Clinical characteristics and risk factors for peripartum cardiomyopathy

African Health Sciences

Volumn 12, Issue 1, 2012, Pages 26-31

  Huang, G Y ^a   Zhang, L Y ^b   Long Le, M A ^a,c   Wang, Le Xin ^a,c  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b LIAOCHENG PEOPLE'S HOSPITAL   (China)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

C reaction protein; Hypertension; Inflammation; Mortality; Peripartum cardiomyopathy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; TROPONIN I;

ADULT; ARTICLE; BRONCHITIS; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERIPARTUM CARDIOMYOPATHY; PNEUMONIA; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; UPREGULATION;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; CHINA; DIURETICS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; LOGISTIC MODELS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROSPECTIVE STUDIES; PUERPERAL DISORDERS; RISK FACTORS; SOCIOECONOMIC FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84859817484     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12:767-778.
2. Abboud J, Murad Y, Chen-Scarabelli C, Saravolatz L, Scarabelli TM. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol 2007; 118:295-303.
3. Fett JD. Understanding peripartum cardiomyopathy. Int J Cardiol 2008; 130:1-2.
4. Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol. 2009; 201:171.e1-5.
5. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 2005; 80:1602-1606.
6. Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007; 100:302-304.
7. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; Quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation 2006; 113:1807-1816.
8. Zhou BF, Wu XG. eds. Handbook for cardiovascular epidemiological studies. Publication House of Peking Union Medical College, Beijing, 1996.
9. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, van der Werf R, Jongbloed JD, Paulus WJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010; 121:2169-2175.
10. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128: 589-600.
11. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of concept pilot study. Circulation 2010; 121:1465-1473.
12. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 2000; 35:701-705.
13. Fett JD, Ansari A. Inflammatory markers and cytokines in peripartum cardiomyopathy: a delicate balance. Expert Opin Ther Targets 2010; 14:895-898.
14. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005; 111:2050-2055.
15. Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL. African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol 2010; 55:654-659.
16. Chari RS, Frangieh AY, Sibai BM. Hypertension during pregnancy: diagnosis, pathophysiology and management. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy. 3rd ed. New York, NY: Wiley-Liss; 1998: 257-273.
17. Tang L, Liu Y, Wang Y, Long C. Phytochemical analysis of an antiviral fraction of Radix astragali using HPLC-DAD-ESI-MS/MS. J Natur Med 2010; 64:182-186.